🌟 Late-Breaking KRAS Program Update at Myrio Therapeutics
As we unveil our latest KRAS program dataset at the #BiotechShowcase during #JPM24, we're excited to share:
✨ Unearthing the Uncommon: We now have isolation of exceptionally rare clones. These clones boast broad binding footprints and unprecedented selectivity, promising a new chapter in precision medicine.
🎯 Exacting Candidates Unveiled: Surpassing expectations, our lead candidates—averaging over 6+ scFv clones per discovery endeavor—have demonstrated remarkable affinity and selectivity, underscoring the promise of our KRAS-targeted programs.
🔬 Dual-Force Antibody Dynamics: Our cutting-edge anti-CD3 bispecific engagers are at the cusp of revolutionizing how T-cells detect and obliterate KRAS-mutated tumor cells, marking a stride in precision oncology.
🛡️ Selective Strike Capability: Demonstrating specificity, our clones uniquely eliminate tumor cells that present mutant KRAS peptides, sparing healthy cells. This in vitro milestone is a testament to the potential lethality of our targeted approach.
🗓️ Futuristic Foresight: With pharmacokinetic and in vivo efficacy studies imminent in late Q2 and Q3 of 2024, respectively, and IND-enabling studies planed in Q4 2025, we're on an accelerated path to the clinic.
🚀 Clinical Ascent for KRAS G12V/HLA-A*11: Advancing our program candidates, we're poised to tackle NSCLC, CRC, and pancreatic cancer head-on. We're actively engaging strategic partners to accelerate our KRAS programs and invite you to participate in this ground-breaking venture.
For a detailed confidential deck, Dr Sinth Jegaskanda, PhD, MIP is standing by.
Join us as we reshape the future of cancer treatment, one precise step at a time. #MyrioTherapeutics #kras #OncologyInnovation #NextGenMedicine #targetedtherapy
Chief Operating and Business Officer at Umoja Biopharma
6moWay to go Naomi and Profound crew